Randomized Double Blind Placebo controlled Clinical study of Ayurvedic coded drug â??AYUSH-Aâ?? in the Management of Bronchial Asthma (TamakaShwasa)

CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES MINISTRY OF AYUSH GOVERNMENT OF INDIA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of any gender with age between 18 to 60 years.
•2.Patients with mild tomoderate stable Bronchial Asthma (TamakaSwasa) (as per GINA
•Guidelines 2020 recommendations) and on regular and stable dose of inhaled therapy (medium â?? high dose ICS alone or ICS+LABA) for at least 4 weeks prior to study entry.
•3.Patients willing to participate and provide written consent.

•1.Patients with H/O acute exacerbation of respiratory symptoms during last four weeks
•2.Patients with evidence of malignancy.
•3.Chronic obstructive pulmonary disease, pneumonia, lung cancer and other chronic lung diseases
•4.Patients under treatment for Pulmonary TB or with a diagnosis of Pulmonary TB.
•5.Patients with uncontrolled Diabetes Mellitus assessed by fasting blood sugar or HbA1c >7.5%.
•6.Patients with unstable cardiovascular disease.
•7.Patients suffering from other major systemic illness necessitating long term drug treatment (eg: Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.)
•8.Pulmonary emphysema, chronic obstructive pulmonary disease, pulmonary emphysema, pulmonary heart disease, pneumonia, lung cancer and other lung diseases
•9.Patients with concurrent serious hepatic disorder or Renal Disorders
•10.Active smokers, alcoholics and/or any form of drug abusers
•11.H/o hypersensitivity to the trial drug or any of its ingredients.
•12.Pregnancy or lactating women.

发起方

CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES MINISTRY OF AYUSH GOVERNMENT OF INDIA